HK1160642A1 - 用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚 - Google Patents

用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚

Info

Publication number
HK1160642A1
HK1160642A1 HK12100967.5A HK12100967A HK1160642A1 HK 1160642 A1 HK1160642 A1 HK 1160642A1 HK 12100967 A HK12100967 A HK 12100967A HK 1160642 A1 HK1160642 A1 HK 1160642A1
Authority
HK
Hong Kong
Prior art keywords
dihydrotetraazabenzoazulenes
arylcyclohexylethers
receptor antagonists
vasopressin
via receptor
Prior art date
Application number
HK12100967.5A
Other languages
English (en)
Inventor
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1160642A1 publication Critical patent/HK1160642A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK12100967.5A 2008-11-28 2012-02-02 用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚 HK1160642A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170188 2008-11-28
PCT/EP2009/065354 WO2010060836A1 (en) 2008-11-28 2009-11-18 Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Publications (1)

Publication Number Publication Date
HK1160642A1 true HK1160642A1 (zh) 2012-08-10

Family

ID=41382009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100967.5A HK1160642A1 (zh) 2008-11-28 2012-02-02 用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚

Country Status (32)

Country Link
US (2) US8227458B2 (zh)
EP (1) EP2370441B1 (zh)
JP (1) JP5452608B2 (zh)
KR (1) KR101359742B1 (zh)
CN (1) CN102227428B (zh)
AR (2) AR074409A1 (zh)
AU (1) AU2009319123B2 (zh)
BR (1) BRPI0922303B1 (zh)
CA (1) CA2743976C (zh)
CO (1) CO6341478A2 (zh)
CR (1) CR20110220A (zh)
CY (1) CY1115435T1 (zh)
DK (1) DK2370441T3 (zh)
EC (1) ECSP11011089A (zh)
ES (1) ES2431279T3 (zh)
HK (1) HK1160642A1 (zh)
HR (1) HRP20131067T1 (zh)
IL (1) IL212122A (zh)
MA (1) MA32781B1 (zh)
MX (1) MX2011005596A (zh)
MY (1) MY150837A (zh)
NZ (1) NZ592076A (zh)
PE (1) PE20110582A1 (zh)
PL (1) PL2370441T3 (zh)
PT (1) PT2370441E (zh)
RU (1) RU2507205C2 (zh)
SG (1) SG171846A1 (zh)
SI (1) SI2370441T1 (zh)
TW (1) TWI379833B (zh)
UA (1) UA103504C2 (zh)
WO (1) WO2010060836A1 (zh)
ZA (1) ZA201103419B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2799020A1 (en) 2010-05-13 2011-11-17 Jennifer R. Allen Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
KR20140082765A (ko) * 2011-10-05 2014-07-02 에프. 호프만-라 로슈 아게 V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌
KR20160042903A (ko) * 2013-08-19 2016-04-20 에프. 호프만-라 로슈 아게 위상 변이 수면 장애의 치료를 위한 V1a 길항제
PL3077396T3 (pl) * 2013-12-05 2021-10-04 F. Hoffmann-La Roche Ag Synteza trans-8-chloro-5-metylo-1-[4-(pirydyn-2-yloksy)¬cykloheksylo]-5,6-dihydro-4h-2,3,5,10b-tetraazabenzo[e]¬azulenu i jego postaci krsytalicznych
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
IL275144B1 (en) * 2017-12-08 2024-08-01 Hoffmann La Roche Pharmacy preparation
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
PT1147115E (pt) 1999-01-19 2004-02-27 Ortho Mcneil Pharm Inc Benzodiazepinas triciclicas como antagonistas do receptor da vasopressina
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
KR100840852B1 (ko) 2004-05-25 2008-06-23 화이자 프로덕츠 인크. 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체
EP1753766A1 (en) 2004-05-25 2007-02-21 Pfizer Products Inc. Tetraazabenzo(e)azulene derivatives and analogs thereof
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
WO2006021882A1 (en) * 2004-08-25 2006-03-02 Pfizer Limited Triazolobenzodiazepines and their use as vasopressin antagonists
US20080188478A1 (en) 2005-04-26 2008-08-07 Pfizer Inc. Compounds Useful In Therapy
WO2006123242A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
AU2008204491B2 (en) 2007-01-12 2012-05-03 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
WO2009125800A1 (ja) * 2008-04-09 2009-10-15 株式会社クラレ ガスバリア性積層体およびその製造方法
PT2356123E (pt) 2008-11-13 2012-10-31 Hoffmann La Roche Espiro-5,6-di-hidro-4h-2,3,5,10b-tetra-azabenzo[ e]azulenos
CN102216304B (zh) * 2008-11-18 2014-07-09 弗·哈夫曼-拉罗切有限公司 二氢四氮杂苯并薁的烷基环己基醚
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes

Also Published As

Publication number Publication date
UA103504C2 (ru) 2013-10-25
RU2507205C2 (ru) 2014-02-20
CN102227428A (zh) 2011-10-26
JP5452608B2 (ja) 2014-03-26
CA2743976C (en) 2017-02-21
TW201024300A (en) 2010-07-01
CA2743976A1 (en) 2010-06-03
IL212122A (en) 2013-06-27
SG171846A1 (en) 2011-07-28
EP2370441B1 (en) 2013-09-11
KR20110077022A (ko) 2011-07-06
MA32781B1 (fr) 2011-11-01
AU2009319123A1 (en) 2010-06-03
US20100137286A1 (en) 2010-06-03
BRPI0922303B1 (pt) 2019-11-12
US20120225865A1 (en) 2012-09-06
US8227458B2 (en) 2012-07-24
AR112338A2 (es) 2019-10-16
EP2370441A1 (en) 2011-10-05
MX2011005596A (es) 2011-06-16
NZ592076A (en) 2012-06-29
PE20110582A1 (es) 2011-08-17
WO2010060836A1 (en) 2010-06-03
ECSP11011089A (es) 2011-06-30
JP2012510441A (ja) 2012-05-10
AR074409A1 (es) 2011-01-12
PT2370441E (pt) 2013-11-14
CO6341478A2 (es) 2011-11-21
HRP20131067T1 (hr) 2013-12-06
CR20110220A (es) 2011-06-21
US8461152B2 (en) 2013-06-11
CY1115435T1 (el) 2017-01-04
SI2370441T1 (sl) 2013-12-31
DK2370441T3 (da) 2013-10-21
TWI379833B (en) 2012-12-21
ZA201103419B (en) 2014-07-30
MY150837A (en) 2014-02-28
IL212122A0 (en) 2011-06-30
RU2011123703A (ru) 2013-01-10
PL2370441T3 (pl) 2014-02-28
AU2009319123B2 (en) 2014-10-23
CN102227428B (zh) 2015-03-25
BRPI0922303A2 (pt) 2016-01-12
KR101359742B1 (ko) 2014-02-06
ES2431279T3 (es) 2013-11-25

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
HK1160642A1 (zh) 用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚
GB2461629B (en) Antagonists of prostaglandin D2 receptors
EP2244575A4 (en) ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR
EP2245022A4 (en) ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
IL212551A0 (en) Cxcr4 receptor compounds
EP2350024A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
ZA201105056B (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
EP2378877A4 (en) IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
IL214731A0 (en) Uses of nk receptor antagonists
ZA201100841B (en) Novel compounds active as muscarinic receptor antagonists
IL209266A0 (en) Pyrrolidine derivatives as nk2 receptor antagonists
EP2365748A4 (en) IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2340025A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2250168A4 (en) ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA201202150B (en) [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
EP2339919A4 (en) BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS
EP2291076A4 (en) Angiotensin-II Receptor Antagonists
EP2408304A4 (en) CGRP RECEPTOR ANTAGONISTS
GB0916792D0 (en) (1,4)-Benzodiazepines as vasopressin V2 receptor antagonists
GB0922455D0 (en) Ep2 receptor antagonists